Using protein biomarkers to improve lung cancer screening decisions
The Lung EArly Proteins project: A LEAP toward implementing biomarkers in lung cancer screening
The LEAP project is looking to improve lung cancer screening by testing a new set of protein markers in blood samples to see if checking these markers multiple times can help doctors make better decisions about when to start screening and when to take a closer look at lung nodules, ultimately aiming to create more tailored and effective screening for people at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International Agency for Res on Cancer NIH-funded |
| Lab location | 1 site (Lyon, France) |
| Project ID | NIH-10909840 on NIH RePORTER |
What this research studies
The Lung EArly Proteins (LEAP) project aims to enhance lung cancer screening by utilizing a novel panel of protein biomarkers. This research focuses on optimizing the decision-making process for initiating screening and determining when to biopsy lung nodules. By analyzing blood samples from lung cancer patients and controls, the project seeks to establish whether repeated measurements of these biomarkers can provide better predictive accuracy for lung cancer development compared to a single measurement. The findings could lead to more personalized and effective screening strategies for at-risk individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research include current and former smokers who are at risk for lung cancer.
Not a fit: Patients who do not smoke or have never smoked may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and timely lung cancer screenings, potentially saving lives through earlier detection.
How similar studies have performed: Previous research has shown promise in using biomarkers for cancer detection, suggesting that this approach could be effective.
Where this research is happening
Lyon, France
- International Agency for Res on Cancer — Lyon, France (Active)
Researchers
- Principal investigator: Robbins, Hilary a. — International Agency for Res on Cancer
- Study coordinator: Robbins, Hilary a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.